Natixis Sells 4,972 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Natixis trimmed its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 20.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,073 shares of the company’s stock after selling 4,972 shares during the quarter. Natixis owned approximately 0.06% of TransMedics Group worth $1,410,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in TMDX. Venturi Wealth Management LLC bought a new stake in TransMedics Group during the first quarter worth about $30,000. Fidelis Capital Partners LLC acquired a new position in shares of TransMedics Group during the first quarter worth approximately $35,000. First Horizon Advisors Inc. lifted its position in shares of TransMedics Group by 26.8% during the fourth quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock worth $83,000 after purchasing an additional 222 shares in the last quarter. Entropy Technologies LP acquired a new position in shares of TransMedics Group during the first quarter worth approximately $201,000. Finally, SG Americas Securities LLC acquired a new position in shares of TransMedics Group during the fourth quarter worth approximately $204,000. 99.67% of the stock is owned by institutional investors.

TransMedics Group Trading Down 2.1 %

NASDAQ TMDX traded down $3.20 during trading hours on Thursday, hitting $145.99. The company’s stock had a trading volume of 470,454 shares, compared to its average volume of 739,061. The stock has a fifty day moving average of $143.16 and a 200 day moving average of $108.24. TransMedics Group, Inc. has a twelve month low of $36.42 and a twelve month high of $156.05. The firm has a market capitalization of $4.81 billion, a P/E ratio of -429.38 and a beta of 1.98. The company has a quick ratio of 8.76, a current ratio of 9.72 and a debt-to-equity ratio of 3.18.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.40. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 7.95%. The business had revenue of $96.90 million for the quarter, compared to analyst estimates of $83.78 million. During the same period in the prior year, the business posted ($0.08) earnings per share. TransMedics Group’s revenue was up 132.9% compared to the same quarter last year. Equities research analysts forecast that TransMedics Group, Inc. will post 0.81 earnings per share for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, Director James R. Tobin sold 15,040 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $106.43, for a total value of $1,600,707.20. Following the completion of the sale, the director now owns 205,171 shares of the company’s stock, valued at $21,836,349.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other TransMedics Group news, Director James R. Tobin sold 15,040 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $106.43, for a total value of $1,600,707.20. Following the completion of the sale, the director now owns 205,171 shares of the company’s stock, valued at $21,836,349.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Tamer I. Khayal sold 63,260 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $108.54, for a total transaction of $6,866,240.40. Following the completion of the sale, the insider now directly owns 9,792 shares of the company’s stock, valued at approximately $1,062,823.68. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 247,667 shares of company stock valued at $30,087,968. Corporate insiders own 7.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Stephens assumed coverage on shares of TransMedics Group in a research report on Tuesday, June 4th. They set an “overweight” rating and a $151.00 target price on the stock. Piper Sandler upped their target price on shares of TransMedics Group from $120.00 to $170.00 and gave the stock an “overweight” rating in a research report on Monday, July 15th. Canaccord Genuity Group upped their target price on shares of TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Cantor Fitzgerald assumed coverage on shares of TransMedics Group in a research report on Thursday, June 6th. They set an “overweight” rating and a $161.00 target price on the stock. Finally, JPMorgan Chase & Co. increased their price objective on shares of TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $146.38.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.